{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:15:38Z","timestamp":1789949738519,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.tiv.2015.07.015","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T01:20:40Z","timestamp":1437182440000},"page":"1887-1896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells"],"prefix":"10.1016","volume":"29","author":[{"given":"Alyssa M.","family":"Keil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erina Y.","family":"Jacinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy J.","family":"Zauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruy","family":"Tchao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Harvison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2015.07.015_b0005","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/BF02980259","article-title":"Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors","volume":"30","author":"Ali","year":"2007","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.tiv.2015.07.015_b0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1021\/tx050353h","article-title":"Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry","volume":"19","author":"Alvarez-S\u00e1nchez","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0015","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1016\/j.bmcl.2012.08.052","article-title":"Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents","volume":"22","author":"Avupati","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2015.07.015_b0020","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0968-0896(01)00366-2","article-title":"Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.","volume":"10","author":"Bruno","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tiv.2015.07.015_b0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/jat.1366","article-title":"Application of structure\u2013activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of \u03b1,\u03b2-unsaturated aldehydes","volume":"28","author":"Chan","year":"2008","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","volume":"41","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.tiv.2015.07.015_b0035","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/ejoc.200400055","article-title":"Synthesis of an optically active decahydro-6-isoquinolone scaffold with a quaternary stereocenter","volume":"2004","author":"Christoffers","year":"2004","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.tiv.2015.07.015_b0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/dom.12101","article-title":"Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?","volume":"15","author":"Consoli","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tiv.2015.07.015_b0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tox.2008.06.006","article-title":"Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats","volume":"250","author":"Crincoli","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2015.07.015_b0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","article-title":"Thiazolidinediones: a new class of antidiabetic drugs","volume":"16","author":"Day","year":"1999","journal-title":"Diabet. Med."},{"key":"10.1016\/j.tiv.2015.07.015_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138920008783331086","article-title":"Cell lines: a tool for in vitro drug metabolism studies","volume":"9","author":"Donato","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tiv.2015.07.015_b0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jmgm.2010.05.008","article-title":"Analysis and comparison of 2D fingerprints: Insights into database screening performance using eight fingerprint methods","volume":"29","author":"Duan","year":"2010","journal-title":"J. Molec. Graph. Model."},{"key":"10.1016\/j.tiv.2015.07.015_b0065","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.tiv.2011.09.015","article-title":"Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells","volume":"25","author":"Frederick","year":"2011","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2015.07.015_b0070","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/jps.21244","article-title":"Alternative measures of lipophilicity: from octanol\u2013water partitioning to IAM retention","volume":"97","author":"Giaginis","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2015.07.015_b0075","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1016\/S0040-4020(00)00361-6","article-title":"Regiospecific reduction of 5-benzylidene-2,4-thiazolidinediones and 4-oxo-2-thiazolidinediones using lithium borohydride in pyridine and tetrahydrofuran","volume":"56","author":"Giles","year":"2000","journal-title":"Tetrahedron"},{"key":"10.1016\/j.tiv.2015.07.015_b0080","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jps.2600800818","article-title":"Synthesis and anticonvulsant evaluation of some new 2-benzylsuccinimides","volume":"80","author":"Goehring","year":"1991","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2015.07.015_b0085","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/dmrr.251","article-title":"Differentiating members of the thiazolidinedione class: a focus on efficacy","volume":"18","author":"Goldstein","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.tiv.2015.07.015_b0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11030-006-9038-0","article-title":"Differences in hepatotoxicity and gene expression profiles by anti-diabetic agonists on rat primary hepatocytes and human HepG2 cells","volume":"10","author":"Guo","year":"2006","journal-title":"Mol. Divers."},{"key":"10.1016\/j.tiv.2015.07.015_b0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/cr60266a001","article-title":"Cyclic carboxylic monoimides","volume":"70","author":"Hargreaves","year":"1970","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tiv.2015.07.015_b0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002040100251","article-title":"Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes","volume":"75","author":"Haskins","year":"2001","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/dmd.32.6.639","article-title":"Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved","volume":"32","author":"He","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2015.07.015_b0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/mutage\/geg018","article-title":"\u03b1,\u03b2-Unsaturated carbonyl compounds: induction of oxidative DNA damage in mammalian cells","volume":"18","author":"Janzowski","year":"2003","journal-title":"Mutagenesis"},{"key":"10.1016\/j.tiv.2015.07.015_b0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/tx000180q","article-title":"Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission","volume":"14","author":"Kassahun","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0300-483X(02)00692-3","article-title":"Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione- and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats","volume":"186","author":"Kennedy","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2015.07.015_b0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14740338.2012.691963","article-title":"Thiazolidinedione safety","volume":"11","author":"Kung","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tiv.2015.07.015_b0130","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/dmrr.252","article-title":"Differentiating members of the thiazolidinedione class: a focus on safety","volume":"18","author":"Lebovitz","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.tiv.2015.07.015_b0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/toxsci\/kfm301","article-title":"Molecular mechanisms of the conjugated \u03b1,\u03b2-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases","volume":"104","author":"LoPachin","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.07.015_b0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/tx5001046","article-title":"Molecular mechanisms of aldehyde toxicity: a chemical perspective","volume":"27","author":"LoPachin","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0145","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1135\/cccc19813097","article-title":"Solvolysis kinetics and mechanism of 3-methyl-1,3-thiazolidine-2,4-dione","volume":"46","author":"Mach\u00e1\u010dek","year":"1981","journal-title":"Coll. Czech. Chem. Commun."},{"key":"10.1016\/j.tiv.2015.07.015_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2133\/dmpk.21.347","article-title":"Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review","volume":"21","author":"Masubuchi","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.tiv.2015.07.015_b0155","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tiv.2015.07.015_b0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cyto.a.10011","article-title":"Troglitazone-induced oxidative stress in rat hepatoma cells: a flow cytometric assessment","volume":"52A","author":"Narayanan","year":"2003","journal-title":"Cytometry, Pt. A"},{"key":"10.1016\/j.tiv.2015.07.015_b0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/jpet.114.213777","article-title":"Novel N-phenyl-substituted thiazolidinediones protect neural cells against glutamate- and t-Bid-induced toxicity","volume":"350","author":"Oppermann","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2015.07.015_b0170","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00044011-200222080-00001","article-title":"Thiazolidinediones. A pharmacological overview","volume":"22","author":"Owens","year":"2002","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.tiv.2015.07.015_b0175","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/00498250701830267","article-title":"Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats","volume":"38","author":"Patel","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tiv.2015.07.015_b0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jat.1639","article-title":"Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats","volume":"32","author":"Patel","year":"2012","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.bmc.2005.08.056","article-title":"In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones","volume":"14","author":"Rakowitz","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tiv.2015.07.015_b0190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/00498250210128675","article-title":"Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells","volume":"32","author":"Rodr\u00edguez-Antona","year":"2002","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tiv.2015.07.015_b0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxlet.2009.10.014","article-title":"Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity","volume":"192","author":"Saha","year":"2010","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tiv.2015.07.015_b0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2012.09.021","article-title":"Pyrrolidionediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties","volume":"697","author":"Saha","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tiv.2015.07.015_b0205","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00002018-200124120-00002","article-title":"Hepatotoxicity with thiazolidinediones. Is it a class effect?","volume":"24","author":"Scheen","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.tiv.2015.07.015_b0210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0215","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1021\/jp308023g","article-title":"Density functional study on the cytochrome-mediated S-oxidation: identification of crucial reactive intermediate on the metabolic path of thiazolidinediones","volume":"116","author":"Taxak","year":"2012","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.tiv.2015.07.015_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/toxsci\/69.1.131","article-title":"Effects of troglitazone on HepG2 viability and mitochondrial function","volume":"69","author":"Tirmenstein","year":"2002","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.07.015_b0225","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/tx0001981","article-title":"Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo","volume":"14","author":"Tettey","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.07.015_b0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tox.2005.08.003","article-title":"An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics","volume":"216","author":"Vignati","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2015.07.015_b0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1386207003331454","article-title":"Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening","volume":"3","author":"Xue","year":"2000","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.tiv.2015.07.015_b0240","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0024-3205(01)01432-1","article-title":"Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells","volume":"70","author":"Yamamoto","year":"2001","journal-title":"Life Sci."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233315001769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233315001769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T21:25:29Z","timestamp":1537478729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233315001769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0887233315001769"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2015.07.015","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2015.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}